GenSight Biologics
gensight-biologics.com
Health Care
Biologics & Biosimilars
Cell & Gene Therapy
As featured in
Claim pageClaim
Follow
Overview
News
Salaries
Products
People
Growth
Offices
Financials
Funding and backers
Total raised
$1.8M
1 round on record
Latest round
$1.8M
Venture round · Mar 2026 · 7 mo ago
Team
1-10
employees, estimated range
Backers
1
Sofinnova Partners
The money's age
Fresh money
7 months since the last round · not hiring
Momentum
35/100
in the news, fresh money
Last sign of life
this month
a posting or a news item
The story so fareach stage dated by its source: the company's releases, the press, registers, filings
Mar 10
Raised a round Venture round $1.8M · Pulse 2.0
Funding rounds
| Round | Date | Amount | Investors | Source |
|---|---|---|---|---|
| Venture round | Mar 2026 | $1.8M | — | Pulse 2.0 |
Backed byfrom the funds' portfolios and accelerator catalogs
Sofinnova Partners Investors in similar startupsfunds that back the companies most like this one
Similar startupsby what they do, their industry and backers
Borea therapeuticsBorea Therapeutics: Next-generation viral vectors for targeted gene therapy.
Alia Therapeutics is a startup which is developing next-generation gene editing medicines to cure genetic diseases.
ProtaGene is a world-leading CRO partner for the biopharmaceutical and gene and cell therapy industries.
GeneVentiv Therapeutics — advancing gene therapy approaches.
Pioneering Cell Therapies for the Central Nervous System. We are a Salt Lake City-based biotechnology company developing novel macrophage…
Bionyra Pharma is a clinical-stage biopharmaceutical company developing next-generation biologics for severe immune-mediated inflammatory…
News
GenSight Biologics Announces the Closing of its €1.0 Million Fundraising Supported by Existing Shareholders
Read more
Report
GenSight Biologics Announces the Closing of its €1.0 Million Fundraising Supported by Existing Shareholders
PARIS, October 16, 2026--Regulatory News: GenSight Biologics (the "Company") (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative dis
Read more
Report
Vidéo - Le Journal des biotechs : Laurence Rodriguez, directrice générale de Gensight - Boursorama
08/10/2026 16:13:01 : GenSight Biologics a franchi plusieurs étapes importantes ces derniers mois avec la reprise des traitements par Lumevoq, les progrès réalisés sur le plan industriel et 8,2 millions d'euros encaissés depuis mars dans le cadre des...
Read more
Report
GenSight Biologics: Pioneer trial on GS030 published in NEJM, visual signals in 6 out of 10 patients
GenSight Biologics and the National Hospital of 15-20 announced on October 8, 2026 the publication, in The New England Journal of Medicine, of the results of the PIONEER trial dedicated to GS030, an optogenetic therapy candidate for retinitis pigmentosa a
Read more
Report
GenSight Biologics and the 15-20 National Hospital Announce NEJM Publication on GS030 Phase 1/2 Trial Results in Late-Stage Retinitis Pigmentosa
Read more
Report
Gensight Biologics and the 15-20 National Hospital Announce NEJM Publication on GS030 Phase 1/2 Trial Results in Late-Stage Retinitis Pigmentosa
PARIS, October 08, 2026--Regulatory News: GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and centra
Read more
Report
GenSight Biologics Announces a Successful €1.0 Million Fundraising Supported by Existing Shareholders
Read more
Report
Gensight Biologics and the 15-20 National Hospital Announce NEJM Publication on GS030 Phase 1/2 Trial Results in Late-Stage Retinitis Pigmentosa
Read more
Report
GenSight Biologics Reports Cash Position as of September 30, 2026
€8.2 million in gross cash collections from paid early access programs since the start of treatments in March 2026, including €1.7 million during the third quarter Paid early access programs continue to generate cash and support the Company's operating ac
Read more
Report
Show more news
Financials
Total raised
$1.8M
Latest round
Venture - Series Unknown
Funding rounds
1
Funding rounds
| Round | Announced | Amount | |
|---|---|---|---|
| Venture - Series Unknown | 2026 | $1.8M | Details |